2022 World Conference on Lung Cancer (ePosters)-EP08.02-149. Spanish Multicenter Retrospective Study of Real-Life Experience of Advanced NSCLC with EGFR Exon 20 Insertions Treated With Amivantamab

EP08.02-149. Spanish Multicenter Retrospective Study of Real-Life Experience of Advanced NSCLC with EGFR Exon 20 Insertions Treated With Amivantamab

Back to course

Pdf Summary

This study provides real-world data on the activity and safety of amivantamab, a novel anti-EGFR/c-MET bispecific antibody, in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) with exon 20 insertions (ex20ins). The study included 10 patients who received amivantamab after progression on standard therapy in an Expanded Access Program (EAP) in Spain.<br /><br />The patients had a median age of 64 years and were predominantly female (58%) and non-smokers (50%). All patients had adenocarcinoma histology, and half had metastases in 2 or 3 sites. Co-occurring mutations were detected in 42% of patients.<br /><br />The study found that 70% of patients experienced any grade of infusional reaction with amivantamab, with 20% experiencing grade 3 reactions. However, no reactions were observed beyond the first dose. The most common adverse events were rash, hypoalbuminemia, fatigue, and elevated AST/ALT levels. Two patients had dose reductions due to grade 3 fatigue and one due to grade 3 elevated AST/ALT.<br /><br />The overall response rate (ORR) with amivantamab was 30%, with all responses being partial responses. The disease control rate (DCR) was 70%, and two patients had progressive disease as the best response. The intracranial DCR was 50% with no observed objective response.<br /><br />At the time of data cut-off, 9 out of 10 patients were still alive, and 8 were still on treatment. The median progression-free survival (PFS) and overall survival (OS) were not reached. The study also included a sequence of previous treatments and outcomes, showing the patients' treatment history.<br /><br />In conclusion, this real-world study demonstrates that amivantamab has clinical activity in patients with EGFR-mutated advanced NSCLC with exon 20 insertions, consistent with previous clinical trial data. The spectrum of adverse events and infusional reactions was similar to previous reports, although there were higher rates of dose reductions and treatment discontinuation compared to clinical trials. Further follow-up is needed to assess survival outcomes.

Asset Subtitle

Víctor Albarrán-Artahona

Meta Tag

Speaker Víctor Albarrán-Artahona

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

amivantamab

anti-EGFR/c-MET bispecific antibody

non-small cell lung cancer

EGFR-mutated

exon 20 insertions

Expanded Access Program

infusional reaction

adverse events

response rate

progression-free survival